Tejal SomvanshiFeeling weaker as you age might feel like a failure of routine or motivation. New research from the University of Copenhagen suggests it is your cells making a rational, if inconvenient, protective decision — and that the mechanism behind it is a fat molecule inside your mitochondria that most people have never heard of.
This is preclinical research. The study was conducted in mice, published and catalogued on PubMed (https://pubmed.ncbi.nlm.nih.gov/42811121/), and its findings cannot be directly translated to human treatments at this stage. But the biology it identifies challenges a common assumption about ageing muscle and the role of antioxidant supplements.
The molecule at the centre of the research is cardiolipin. It is a lipid — a type of fat — embedded in the inner membrane of mitochondria, the structures inside cells that produce energy. As animals age, cardiolipin levels in muscle tissue fall. The Copenhagen team found that this fall is not merely a side effect of getting older — it is a trigger. When cardiolipin drops, muscles shift their fibre composition from fast-twitch to slow-twitch.
Fast-twitch fibres generate powerful, explosive force. Slow-twitch fibres are more endurance-oriented and less powerful. The shift from fast to slow is exactly what most people notice as they age: explosive strength and power go first, before endurance capacity does. The study’s argument is that this shift is not accidental — it is a cellular defence.
Why your cells choose slow-twitch over fast-twitch as you age
When fast-twitch fibres generate energy rapidly, they produce reactive oxygen species — ROS — as a byproduct. ROS are unstable molecules that can damage cell structures including DNA and proteins. As cardiolipin drops with age, the mitochondria become less efficient at managing ROS. The muscle’s response, in the mouse model, is to shift toward slow-twitch fibres, which generate energy more slowly and produce less ROS. The muscle becomes weaker, but the cell protects itself from damage.
In the mouse study, when the researchers restored cardiolipin levels, the muscle fibres shifted back toward fast-twitch composition and the mice regained strength. That is a striking result. But it is a laboratory result in an animal model. Translating a cardiolipin restoration approach to humans would require identifying a safe and effective way to raise the lipid in human muscle tissue, which is not currently a standard clinical option.
The antioxidant finding is equally important. A common assumption in fitness and sports science is that antioxidant supplements — designed to neutralise ROS — should help ageing muscles by removing the thing the cell is defending against. In this mouse study, antioxidant supplementation actually worsened muscle health. The researchers’ interpretation is that the ROS the antioxidants were neutralising also function as signalling molecules the cell needs to regulate its own stress response. Removing them disrupted that signal.
This does not mean all antioxidant supplementation is harmful. The study was conducted in a specific mouse model under controlled conditions, and its findings apply directly to that context. But it challenges the logic of treating all ROS as simply bad and all antioxidant supplementation as simply good — especially in the context of muscle ageing.
The cardiolipin finding opens a different line of enquiry into why muscles age the way they do. Instead of starting from muscle protein — the usual focus — it starts from the mitochondrial membrane and the lipid environment in which mitochondria operate. That is a distinct biological layer that has received less research attention.
For older adults thinking about muscle health, the practical upshot is currently limited: there is no approved cardiolipin supplement or therapy. The value of this study is in shifting the scientific framework. If muscle loss in ageing is partly a cardiolipin-driven mitochondrial protection response rather than simply a protein-synthesis failure, then the interventions that work are likely to be different from the ones currently emphasised. Further human research is needed before clinical conclusions can be drawn. The University of Copenhagen study is a preclinical step, not a treatment protocol.
Broader research into ageing biology sits within a global health picture shaped by fiscal and political priorities. In Australia, dementia has overtaken conditions once ranked below it as a leading cause of death, now claiming more than 19,000 lives annually (https://www.karmactive.com/dementia-19019-deaths-australia-asthma-decade-high-2025/), placing muscle-loss and neurodegeneration research in direct public health context. France’s health budget pressures this year have been acute (https://www.karmactive.com/france-bond-yields-protests-limoges-fire-2026/), and extreme weather events affecting populations and ecosystems — as seen with Cyclone Arnab’s impact on eastern India (https://www.karmactive.com/cyclone-arnab-andhra-pradesh-trains-cancelled-dead/) — shape the population health contexts in which ageing research finds its application.
